Please login to the form below
rare autoimmune disease
This page shows the latest rare autoimmune disease news and features for those working in and with pharma, biotech and healthcare.
GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
The rare autoimmune disease affects two to ten people per million and has limited treatments. ... Affecting two to ten people per million, SSc is a rare autoimmune disease that causes unusual growth of connective tissues and can affect a patient’s
Latest news
-
Amgen announces plans to acquire Horizon for $27.8bn in biggest pharma deal for 2022
criteria’. Amgen will benefit from gaining several approved therapies as part of the deal, with Horizon’s pipeline of rare autoimmune and inflammatory disease drugs bolstering Amgen’s offering. ... Included in this is Horzion’s Tepezza, a
-
Sanofi’s Enjaymo receives EC approval for rare autoimmune haemolytic anaemia
Cold agglutinin disease affects around 12, 000 people in the US, Europe and Japan. ... Enjaymo is currently the only approved treatment for CAD, a rare type of autoimmune haemolytic anaemia where part of the body’s immune system mistakenly destroys
-
Alexion's Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial
Alexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) significantly reduced relapse risk in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) compared to an ... NMOSD is a rare
-
NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia
ITP is a rare autoimmune condition characterised by the destruction of platelets, which play an active role in blood clotting and healing. ... Tavlesse is the first new drug for treating chronic ITP in over a decade, addressing the unmet needs of
-
EC approves Alexion's Ultomiris as generalised myasthenia gravis treatment
The European Commission (EC) has approved Aexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) in Europe as an add-on to standard therapy for generalised myasthenia gravis (gMG). ... gMG is a rare, debilitating, chronic,
More from news
Approximately 1 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
The distressing impact of rare diseases
The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
Genetic Digital
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
